albumin/factor IX parenteral; albutrepenonacog alfa (Idelvion)
Jump to navigation
Jump to search
Indications
- hemophilia B
- as-needed control & prevention of bleeding episodes
- managing perioperative bleeding
Pharmacokinetics
- longer 1/2life than recombinant factor IX
More general terms
References
- ↑ FDA News Release. March 4, 2016 FDA approves first coagulation factor-albumin fusion protein to treat patients with hemophilia B. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm489266.htm